Broadfin Capital Boosted Its Catalyst Pharmaceuticals (CPRX) Stake; 5 Analysts Bullish Flotek Industries, Inc. (FTK)

May 20, 2018 - By Winifred Garcia

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Logo

Among 6 analysts covering Flotek Industries (NYSE:FTK), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Flotek Industries had 13 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was upgraded by Oppenheimer on Monday, July 27 to “Perform”. Vetr upgraded it to “Buy” rating and $20.11 target in Tuesday, September 22 report. The company was maintained on Tuesday, February 27 by Seaport Global. On Wednesday, January 17 the stock rating was maintained by Seaport Global with “Buy”. On Monday, December 14 the stock rating was initiated by KLR Group with “Buy”. The firm earned “Buy” rating on Thursday, August 6 by Vetr. Vetr downgraded Flotek Industries, Inc. (NYSE:FTK) on Friday, August 28 to “Strong-Buy” rating. Oppenheimer maintained Flotek Industries, Inc. (NYSE:FTK) on Wednesday, October 7 with “Perform” rating. The company was maintained on Tuesday, April 24 by Seaport Global. Seaport Global Securities upgraded the shares of FTK in report on Wednesday, January 20 to “Speculative Buy” rating. See Flotek Industries, Inc. (NYSE:FTK) latest ratings:

24/04/2018 Broker: Seaport Global Rating: Buy New Target: $5.0000 Maintain
27/02/2018 Broker: Seaport Global Rating: Buy New Target: $8.0 Maintain
17/01/2018 Broker: Seaport Global Rating: Buy New Target: $7.0 Maintain

Broadfin Capital Llc increased Catalyst Pharmaceuticals Inc (CPRX) stake by 2.97% reported in 2017Q4 SEC filing. Broadfin Capital Llc acquired 204,800 shares as Catalyst Pharmaceuticals Inc (CPRX)’s stock declined 36.55%. The Broadfin Capital Llc holds 7.10 million shares with $27.75 million value, up from 6.89M last quarter. Catalyst Pharmaceuticals Inc now has $342.67M valuation. It closed at $3.34 lastly. It is down 24.38% since May 20, 2017 and is uptrending. It has outperformed by 12.83% the S&P500.

Since May 15, 2018, it had 4 insider buys, and 0 sales for $240,010 activity. Shares for $114,552 were bought by CHISHOLM JOHN on Tuesday, May 15. 10,216 shares were bought by SNIVELY JOSHUA A, worth $34,787 on Tuesday, May 15. The insider Walton H. Richard bought $67,684. On Tuesday, May 15 Marietta Matthew B bought $22,987 worth of Flotek Industries, Inc. (NYSE:FTK) or 6,850 shares.

Investors sentiment decreased to 0.7 in Q4 2017. Its down 1.14, from 1.84 in 2017Q3. It dived, as 24 investors sold Flotek Industries, Inc. shares while 45 reduced holdings. 18 funds opened positions while 30 raised stakes. 42.92 million shares or 9.44% less from 47.40 million shares in 2017Q3 were reported. Fred Alger Mngmt invested 0.01% in Flotek Industries, Inc. (NYSE:FTK). Teachers Retirement Sys Of The State Of Kentucky owns 0% invested in Flotek Industries, Inc. (NYSE:FTK) for 11,300 shares. Tiaa Cref Inv Management Limited accumulated 136,315 shares. The Missouri-based Stifel Fin has invested 0.01% in Flotek Industries, Inc. (NYSE:FTK). Wells Fargo Com Mn reported 56,476 shares stake. Manufacturers Life Insur Commerce The owns 0% invested in Flotek Industries, Inc. (NYSE:FTK) for 43,993 shares. California State Teachers Retirement System reported 87,774 shares stake. Walleye Trading Ltd Liability Co, Minnesota-based fund reported 9,047 shares. Citigroup stated it has 1,070 shares. 44,174 are held by American Group. Barclays Public Lc reported 0% of its portfolio in Flotek Industries, Inc. (NYSE:FTK). Pnc Finance Svcs Group Inc owns 0% invested in Flotek Industries, Inc. (NYSE:FTK) for 2,712 shares. Goldman Sachs Gp accumulated 215,029 shares or 0% of the stock. Arcadia Corporation Mi holds 0.01% or 10,000 shares in its portfolio. Invesco Limited owns 2.62M shares.

Flotek Industries, Inc. develops and supplies chemistry and services to the gas and oil industries in the United States and internationally. The company has market cap of $199.02 million. It operates through two divisions, Energy Chemistry Technologies and Consumer and Industrial Chemistry Technologies. It currently has negative earnings. The Energy Chemistry Technologies segment is involved in the design, development, manufacture, packaging, and marketing of chemistries under the Complex nano-Fluid brand name for use in gas and oil well drilling, cementing, completion, stimulation, and production activities, as well as for use in enhanced and improved oil recovery markets.

The stock decreased 2.51% or $0.09 during the last trading session, reaching $3.5. About 1.21 million shares traded. Flotek Industries, Inc. (NYSE:FTK) has declined 46.23% since May 20, 2017 and is downtrending. It has underperformed by 57.78% the S&P500.

Another recent and important Flotek Industries, Inc. (NYSE:FTK) news was published by Seekingalpha.com which published an article titled: “Flotek Industries’ (FTK) CEO John Chisholm on Q1 2018 Results – Earnings Call Transcript” on May 10, 2018.

More news for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) were recently published by: Globenewswire.com, which released: “Catalyst Pharmaceuticals Introduces New Corporate Website” on April 24, 2018. Seekingalpha.com‘s article titled: “Catalyst Pharmaceutical Partners’ (CPRX) CEO Patrick McEnany on Q1 2018 Results – Earnings Call Transcript” and published on May 10, 2018 is yet another important article.

Among 5 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals had 15 analyst reports since April 26, 2016 according to SRatingsIntel. The rating was maintained by Piper Jaffray on Monday, August 7 with “Buy”. The stock of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has “Neutral” rating given on Tuesday, April 26 by Piper Jaffray. The firm has “Buy” rating given on Wednesday, August 30 by Roth Capital. The firm has “Overweight” rating given on Wednesday, October 5 by PiperJaffray. The firm earned “Buy” rating on Friday, November 10 by H.C. Wainwright. The stock of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) earned “Buy” rating by Roth Capital on Thursday, August 10. The firm earned “Buy” rating on Tuesday, October 31 by SunTrust. SunTrust maintained it with “Buy” rating and $5.0 target in Friday, September 1 report. H.C. Wainwright maintained the stock with “Buy” rating in Friday, August 11 report. Piper Jaffray maintained the shares of CPRX in report on Friday, December 1 with “Buy” rating.

Broadfin Capital Llc decreased Recro Pharma Inc (NASDAQ:REPH) stake by 664,061 shares to 2.44 million valued at $22.53 million in 2017Q4. It also reduced Mirati Therapeutics Inc (NASDAQ:MRTX) stake by 43,055 shares and now owns 2.45 million shares. La Jolla Pharmaceutical Co (NASDAQ:LJPC) was reduced too.

Investors sentiment decreased to 1.97 in 2017 Q4. Its down 0.03, from 2 in 2017Q3. It dropped, as 11 investors sold CPRX shares while 19 reduced holdings. 34 funds opened positions while 25 raised stakes. 55.25 million shares or 59.14% more from 34.72 million shares in 2017Q3 were reported. Voya Invest Management Ltd reported 0% stake. Parallax Volatility Advisers Limited Partnership has invested 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Schwab Charles Investment accumulated 148,704 shares or 0% of the stock. Colorado-based Alps has invested 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Sei Investments holds 0% or 1,250 shares. American International Gp invested in 0% or 48,193 shares. Citadel Advsr Limited owns 153,834 shares. Rhumbline Advisers holds 0% or 62,517 shares in its portfolio. Morgan Stanley reported 851,134 shares. Hightower Limited Liability Company has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 10,411 shares. Sphera Funds Management Ltd has invested 0.26% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Moreover, Credit Suisse Ag has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 21,627 shares. Wells Fargo & Mn invested in 39,415 shares. Kennedy Cap Mgmt reported 0.06% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). First Allied Advisory Services holds 0% or 26,000 shares in its portfolio.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>